ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 1000 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

ישראל - עברית - Ministry of Health

neopharm ltd - bazedoxifene as acetate 20 mg - coated tablets - bazedoxifene - conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. a significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. when determining the choice of conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit

ישראל - עברית - Ministry of Health

unipharm ltd - valsartan 40 mg - film coated tablets - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ישראל - עברית - Ministry of Health

מדיקל טכנולוג'יקל קו. mtc - רופא

ישראל - עברית - Ministry of Health

shina systems l.t.d. - מומחה - פתרונות הדמייה )tc ( למערכת הקרדיווסקולארית

ישראל - עברית - Ministry of Health

אלדן ציוד אלקטרוני בע"מ - צוות טכני - הערכת המערכת הקרדיופולמונרית והרכב גוף

ישראל - עברית - Ministry of Health

אלדן ציוד אלקטרוני בע"מ - צוות טכני - הערכת המערכת הקרדיופולמונרית והרכב גוף

ישראל - עברית - Ministry of Health

גאמידה בע"מ - רופא - הפרעות בקצב הלב

ישראל - עברית - Ministry of Health

medlab ltd - רופא - דפיברילטור להשתלה בבני אדם

ישראל - עברית - Ministry of Health

קלינטיקה בע"מ - צוות טכני - מוניטורים לבדיקת פרמטרים חיוניים